Bacil Pharma Limited (BOM:524516)
India · Delayed Price · Currency is INR 12.30
+0.44 (3.71%)
At close: Aug 21, 2026
Bacil Pharma Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 5.69 | 28.57 | 0.41 | 0.29 | 2.3 |
Trading Asset Securities | - | - | - | - | 1.91 | 0.76 |
Cash & Short-Term Investments | 5.69 | 5.69 | 28.57 | 0.41 | 2.2 | 3.06 |
Cash Growth | -80.10% | -80.10% | 6788.85% | -81.12% | -28.26% | 28.71% |
Accounts Receivable | - | 11.8 | - | - | - | - |
Receivables | - | 11.8 | - | - | - | - |
Other Current Assets | - | 0.05 | 0.5 | 0.11 | 0.09 | 0.1 |
Total Current Assets | - | 17.53 | 29.07 | 0.52 | 2.29 | 3.16 |
Property, Plant & Equipment | - | - | - | 0.06 | 0.08 | 0.11 |
Long-Term Investments | - | 242.4 | 213.57 | 6.11 | 2.36 | 2.36 |
Long-Term Deferred Tax Assets | - | 6.19 | 0.54 | 0.56 | 1.17 | 1.08 |
Other Long-Term Assets | - | -0 | 0 | - | 0 | -0 |
Total Assets | - | 273.93 | 256 | 13.26 | 11.27 | 12.72 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | 0.2 | 0.04 | 0.04 | 0 | 0.11 |
Accrued Expenses | - | 23.81 | - | 0.09 | 0.06 | 0.02 |
Short-Term Debt | - | - | 1.64 | 0.98 | 0.21 | 0.33 |
Other Current Liabilities | - | 1.8 | 0.01 | 0.02 | 0.01 | 0.02 |
Total Current Liabilities | - | 25.8 | 1.69 | 1.13 | 0.28 | 0.47 |
Other Long-Term Liabilities | - | -0 | 0 | - | 0 | - |
Total Liabilities | - | 25.8 | 1.69 | 1.13 | 0.28 | 0.47 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 139.7 | 139.7 | 58.9 | 58.9 | 58.9 |
Retained Earnings | - | 108.42 | 114.61 | -53.14 | -54.28 | -53.03 |
Comprehensive Income & Other | - | - | - | 6.37 | 6.37 | 6.37 |
Shareholders' Equity | 248.13 | 248.13 | 254.31 | 12.13 | 10.99 | 12.24 |
Total Liabilities & Equity | - | 273.93 | 256 | 13.26 | 11.27 | 12.72 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | - | - | 1.64 | 0.98 | 0.21 | 0.33 |
Net Cash (Debt) | 5.69 | 5.69 | 26.93 | -0.57 | 1.99 | 2.73 |
Net Cash Growth | -78.89% | -78.89% | - | - | -27.11% | 338.69% |
Net Cash Per Share | - | 0.41 | 4.27 | -0.10 | 0.33 | 0.46 |
Filing Date Shares Outstanding | - | 14.13 | 14.35 | 5.89 | 5.89 | 5.89 |
Total Common Shares Outstanding | - | 14.13 | 14.35 | 5.89 | 5.89 | 5.89 |
Working Capital | - | -8.27 | 27.39 | -0.61 | 2.01 | 2.69 |
Book Value Per Share | 17.56 | 17.56 | 17.72 | 2.06 | 1.87 | 2.08 |
Tangible Book Value | 248.13 | 248.13 | 254.31 | 12.13 | 10.99 | 12.24 |
Tangible Book Value Per Share | 17.56 | 17.56 | 17.72 | 2.06 | 1.87 | 2.08 |
Machinery | - | - | 0.59 | 0.55 | 0.59 | 0.59 |